TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06712186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Group / Group D
Description: In this study, the intervention involve administrating 0.5 mcg/kg of Inj dexmedetomidine intravenously over 10 min to patients in intervention group/group D 2 minutes prior to Endotracheal intubation using laryngoscopy aiming to asses its efficacy in attenuating the pressor response to laryngoscopy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: The Placebo group / group C will be administer Normal Saline without any active medication over 10 min to patients, 2 minutes prior to Endotracheal intubation using laryngoscopy to compare its effect to those of Dexmedetomidine in attenuating the pressor response to laryngoscopy.
Study: NCT06718387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PsychoEducation Program
Description: 6 sessions of PsychoEducational Program
Study: NCT06731712

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Function Exercises
Description: Physical function interventions included strength, balance, and mobility exercises. More specifically, the exercises include progressively increasing intensity strengthening exercises with a resistance band for the following muscle groups: hip abductor and extensor muscles, knee flexor and extensor muscles, and shoulder abductor and external rotator muscles. Other exercises consist of standing calf raises, squats, bridges, and push-ups. Additionally, functional exercises include heel-to-toe standing or walking, single-leg standing, stepping over obstacles, bending down, and lifting an object with feet together.
Study: NCT06731595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: colchicine 0.6mg oral twice daily for 7 days
Study: NCT04158973

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine VTE prophylaxis in hospital
Description: Patients randomized to the standard treatment (Control) group will receive routine VTE prophylaxis according to current guidelines and clinical practices, VTE risk assessment and prophylaxis if indicated during hospitalization according to current policies for hospitals in China but no further treatment prophylaxis after discharge
Study: NCT06731088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam, a benzodiazepine sedative commonly used in ICU, acts on GABA receptors in the central nervous system to produce dose-related hypnosis, anti-pyroanxiety and anterograde amnesia, and has corresponding competitive antagonists \[8\]. It has rapid onset and short duration, but its deficiency lies in that the metabolites are still active. Thus easy accumulation, prolong the recovery time of patients
Study: NCT06309264

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phonak Lumina P90
Description: FDA approved hearing aid with gain settings determined either by speech-based audiometry or conventional fitting methods (NAL-NL2). Other features such as noise reduction and directional microphones are disabled for the duration of the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Lumina P90
Description: FDA approved hearing aid with gain settings determined either by speech-based audiometry or conventional fitting methods (NAL-NL2). Other features such as noise reduction and directional microphones are disabled for the duration of the study.
Study: NCT06077877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4524101
Description: GSK452101 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4524101
Description: GSK452101 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4524101
Description: GSK452101 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4524101
Description: GSK452101 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered.
Study: NCT06731088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remazolam besylate
Description: Remazolam besylate is a new type of benzodiazepine sedative drug metabolized by tissue esterase. It is not metabolized by liver and kidney, and is metabolized by tissue esterase rapidly in vivo to produce inactive metabolites.
Study: NCT06730308

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Hypofractionated radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy
Description: weekly albumin-bound paclitaxel (50 mg/m²) and cisplatin (25 mg/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 2mg/kg, qd, concurrent with radiotherapy
Study: NCT06730282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danggui Shaoyao San (DSS)
Description: Danggui Shaoyao San is a traditional Chinese medicine (TCM) formula used to regulate blood flow, alleviate pain, and reduce inflammation. Participants in this arm will receive DSS starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cuscuta Chinensis (Tu Si Zi)
Description: Cuscuta Chinensis is a TCM formula traditionally used to nourish kidney essence and improve menstrual health. Participants in this arm will receive Tu Si Zi starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.
Study: NCT06077877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niraparib
Description: Niraparib will be administered.
Study: NCT06730282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Therapy (DSS + Tu Si Zi)
Description: This intervention combines Danggui Shaoyao San and Cuscuta Chinensis. Participants will receive both formulas starting 3 to 7 days before menstruation and continue until 3 days after menstruation for two cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this arm will receive a placebo that matches the appearance of the study medications. The placebo will be administered on the same schedule as the active treatments for two menstrual cycles.
Study: NCT06731374

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV15
Description: VAXNEUVANCE (Merck, Sharp \& Dohme LLC, a subsidiary of Merck \& Co, Inc., Rahway, NJ, USA \[MSD\]) is a 15-valent PCV containing capsular polysaccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 22F, and 33F adjuvanted with aluminium phosphate.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae serotype 3
Description: Streptococcus pneumoniae SPN3 (Clade Ia, strain LIV014-S3) - Single inoculation at 80,000 colony-forming unit (CFU)/naris, 28 days after vaccination.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Streptococcus pneumoniae serotype 3
Description: Streptococcus pneumoniae SPN3 (Clade Ia, strain LIV014-S3) - Single inoculation at 80,000 colony-forming unit (CFU)/naris, 28 days after vaccination.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of 0.9% sodium chloride for injection
Study: NCT06730165

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: Stimulation of the vagus nerve through the tragus and concha in the ear

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: Stimulation of the vagus nerve through the tragus and concha in the ear

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Auricular Trigeminal Nerve Stimulation
Description: Stimulation of the trigeminal nerve via the auriculotemporal nerve with a clip electrode from the upper auricle
Study: NCT06038227

Intervention type: PROCEDURE
Intervention: Robotic Assisted Thoracic Surgery
Description: Surgeons will pre-determine to perform a segmentectomy or lobectomy using RATS.

Intervention type: PROCEDURE
Intervention: Video Assisted Thoracic Surgery
Description: Surgeons will pre-determine to perform a segmentectomy or lobectomy using VATS.
Study: NCT05989321

Intervention type: PROCEDURE
Intervention: PVI alone
Description: pulmonary vein isolation
Study: NCT04915547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group-Based Exercise
Description: Each group session will consist of 10 to 18 participants and each exercise session will last 60 minutes and consist of four stages: (1) five minutes warm up (i.e. self-regulated walk); (2) twenty minutes of moderate intensity walking (3) thirty minutes of resistance training for the major muscles of the leg, trunk and arm and balance exercises that progress in difficulty; (4) five-minute cool down period (i.e. self-regulated walk). The exercise intensity will be assessed by one of the following criteria: 1) Resistance training - Point of volitional fatigue. Walking - Somewhat difficult (Borg at 3 to 4). The intensity will be increased according to the ACSM guideline.~The exercise was set up based on changes in instruments of evaluation of the older peoples as, Berg Balance Scale; Dynamic Gait Index and Timed Up and Go. In addition, exercises commonly used in primary health care groups. The protocol will take place in a gymnasium and will be supervised by a trained instructor.
Study: NCT06730165

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Auricular Trigeminal Nerve Stimulation
Description: Stimulation of the trigeminal nerve via the auriculotemporal nerve with a clip electrode from the upper auricle
Study: NCT06731491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Training
Description: Strength and aerobic training in the same training session for a period of 12 weeks, 3 times a week and with an average training time of 60 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Training
Description: Strength and aerobic training in the same training session for a period of 12 weeks, 3 times a week and with an average training time of 60 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Training
Description: Strength and aerobic training in the same training session for a period of 12 weeks, 3 times a week and with an average training time of 60 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy and Aromatherapy
Description: Massage Therapy with Aromatherapy twice a week for a period of 12 weeks and an average time of 40 minutes per session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy and Aromatherapy
Description: Massage Therapy with Aromatherapy twice a week for a period of 12 weeks and an average time of 40 minutes per session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy and Aromatherapy
Description: Massage Therapy with Aromatherapy twice a week for a period of 12 weeks and an average time of 40 minutes per session.
Study: NCT06505278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide in the evening
Description: Participants receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide between 10:00 pm and 12:00 pm in the evening.
Study: NCT04977414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Making Data Count Training intervention
Description: The Making Data Count training intervention was designed by NHS-Improvement to improve knowledge about SPC charts and to increase their uptake. Training sessions are tailored for two sets of attendees: board members and data analysts. Board member and analyst training sessions are delivered as close as possible in time, typically within the same month. Training sessions for board members are usually delivered over about one-and-a-half hours and focus more heavily on the benefits of control charts compared to other charts. Training sessions for analysts are usually delivered over three hours and focus more heavily on the structure and interpretation of the individual and moving range charts (X-mR charts).
Study: NCT06272006

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally Positioned Flap with Connective Tissue Graft
Description: his intervention involves surgically repositioning the gum tissue over the exposed tooth root and adding a connective tissue graft. The graft is obtained from the patient's palate and placed in the area of gingival recession to promote tissue regeneration and enhance root coverage. The procedure aims to reduce gingival recession and improve periodontal health.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Coronally Advanced Tunnel with Connective Tissue Graft
Description: This intervention utilizes a minimally invasive technique to create a tunnel beneath the gum tissue, through which a connective tissue graft is placed. The graft, sourced from the patient's palate, is used to encourage the growth of new gum tissue over the exposed root. This method is designed to minimize trauma and promote faster recovery, aiming to improve root coverage and periodontal outcomes.
Study: NCT05247021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae block for group E
Description: . The patient will be placed in the prone position. A high-frequency linear probe or a curved array probe, depending on the BMI of the patient, will be placed in longitudinal alignment, 2-3cm lateral to the vertebral column. The transverse processes of the vertebrae at the level of surgery, the erector spinae muscle, and the psoas muscle will be identified. A 5- or 8-cm 22-G ultrasound needle will be inserted with an in-plane technique in a cephalad-to-caudal direction until bone contact with the top of the transverse process is reached. After slight retraction of the needle, 20ml of bupivacaine 0.25% will be injected behind the erector spinae muscle. The same procedure will be repeated on the contralateral side.
Study: NCT05735912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided radio frequency ablation
Description: Radiofrequency ablation performed under endoscopic ultrasound guidance of pancreatic insulinoma

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgical resection of pancreatic insulinoma
Study: NCT05933564

Intervention type: OTHER
Intervention: No intervention (cross-sectional study)
Description: This is a cross-sectional study examining the association between cognitive reserve, pain catastrophizing, and cognitive function in geriatric patients with chronic pain; no intervention is being implemented or tested.
Study: NCT05940025

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MORT-LBP
Description: The MORT-LBP, developed by EverEx, Inc., is designed to provide multidisciplinary rehabilitation treatment, a combination of graded exercise therapy and cognitive behavioral therapy for patients with chronic lower back pain.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual (TAU)
Description: In the control group, education and physiotherapy is delivered and self-exercise is recommended.
Study: NCT04916314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate diet
Description: Second Nature is a three-month remote behavioural change programme with mentoring from a registered dietitian or nutritionist (health coach), encouraging adoption of a low energy, low-carbohydrate diet, peer group support, structured education articles and activity tracking technology. These elements are accessed via a smartphone or web-based application; each participant additionally receives an instructional handbook, and recipe book (+/-wireless weighing and activity tracking technology).
Study: NCT06017336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training Group
Description: Patients in the inspiratory muscle training group will be given inspiratory muscle strength training with the Powerbreathe® (inspiratory muscle training device) device at 50% of the maximal inspiratory pressure, 2 sets of 15 minutes a day for a total of 30 min/day or a single set of 30 min/day, 7 days/week for 8 weeks. Patients in the inspiratory muscle training group will continue their respiratory muscle strength training with a home program 6 days a week under the supervision of a physiotherapist 1 day a week. The MIPs of the patients will be re-measured every week and the training workload will be determined at 50% of the new maximal inspiratory pressure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group (breathing exercises)
Description: Thoracic expansion exercises will be given to the control group as a home program. The control group will be asked to do thoracic expansion exercises seven days/week and 120 times/day for eight weeks. The patients in the control group will be called once a week to check their home schedules, and they will be asked to keep a diary.
Study: NCT04661514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Psilocybin-assisted psychotherapy
Study: NCT05266625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BT-001
Description: Bt-001 is a software application that delivers treatment to participants with type 2 diabetes, using behavioral therapy. BT-001 is accessed via the participants' smartphone.~The behavioral intervention process involves:~Identifying maladaptive thoughts based on misinformed core beliefs that lead to disease-promoting behaviors; replacing maladaptive core beliefs with adaptive ways of thinking; and providing collaborative construction of behavioral exercises to test core beliefs.~Each week, Bt-001 asks participants to complete a new lesson, along with one skill exercise. The lessons are expected to take between 10-20 minutes to complete. In addition to completing a lesson and skill, participants will be directed to report plant-based meals consumed and minutes of exercise completed and to measure their blood sugar daily.

Intervention type: OTHER
Group type: OTHER
Intervention: Control App
Description: The app asks patients brief questions about their health but does not include any behavioral therapy.
Study: NCT06009445

Intervention type: DIAGNOSTIC_TEST
Intervention: Renal resistive index
Description: The calculation formula for Renal resistive index (RRI) as follows :~(systolic peak flow velocity _ diastolic minimum flow velocity )/systolic peak flow velocity .~will be measured with ultrasound-Doppler using an abdominal curvilinear probe ultrasonography by two independent, trained sonographers (who will not be involved in patient care. After visualizing the kidney in ultrasound mode and checking for renal abnormalities, an arcuate or interlobar artery will be localized and three successive doppler measurements at different positions in the kidney (high, middle and low) will be performed, 3 times in each kidney. So a total number of 9 RRI values will be obtained in each kidney.~The median value of each section will be used and the 3 median values of each kidney will be averaged.

Intervention type: DIAGNOSTIC_TEST
Intervention: Renal resistive index
Description: The calculation formula for Renal resistive index (RRI) as follows :~(systolic peak flow velocity _ diastolic minimum flow velocity )/systolic peak flow velocity .~will be measured with ultrasound-Doppler using an abdominal curvilinear probe ultrasonography by two independent, trained sonographers (who will not be involved in patient care. After visualizing the kidney in ultrasound mode and checking for renal abnormalities, an arcuate or interlobar artery will be localized and three successive doppler measurements at different positions in the kidney (high, middle and low) will be performed, 3 times in each kidney. So a total number of 9 RRI values will be obtained in each kidney.~The median value of each section will be used and the 3 median values of each kidney will be averaged.
Study: NCT05511558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-Fosgonimeton
Description: Carbon-14 Radiolabeled Fosgonimeton
Study: NCT06153498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: After a loading dose of 0.05mg/kg, a maintaining dose of 0.2mg/kg/h is given; It is recommended to adjust the infusion rate of Remazolam besylate for injection at a amplitude of 0.05mg/kg/h, mainly based on the RASS score of the subjects (the adjustment range is 0-1.0 mg/kg/h, and the maximum infusion rate is not more than 1.0mg/kg/h) until the subjects reach the optimal sedation level (-3≤RASS≤0).
Study: NCT05433480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-16350
Description: BPI-16350 400 mg, orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo 400 mg, orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500 mg intramuscular injection on day 1 and day 15 for the first cycle and then on day 1 for every cycle until progressive disease
Study: NCT05608278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bergen 4-Day Treatment (B4DT)
Description: Novel CBT treatment
Study: NCT05608278

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gold standard cognitive behavioral therapy (gold standard CBT)
Description: Gold standard CBT treatment
Study: NCT05571306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: four core components care
Description: The intervention progresses throughout the first three months for the recently diagnosed T2DM patients and is divided into four core components: 1) Improve of cross-sectoral communication and information sharing, 2) ensure systematism in care, 3) guarantee participation at a one-stop-shop and a start-up conversation at the municipality, and 4) improve patients coping skills.
Study: NCT05019885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Three times a week (M, W, F) for 2 consecutive weeks.
Study: NCT05989321

Intervention type: PROCEDURE
Intervention: PVI + SPs ablation
Description: pulmonary vein isolation + SPs ablation
Study: NCT06542159

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Online adaptive SBRT
Description: Online adaptive SBRT (without PTV expansion margin). The total dose will be 45-50Gy/3-4 fractions, administered once daily. FBCT and 4DCT will be acquired.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional SBRT
Description: SBRT with PTV expansion. The total dose will be 45-50Gy/3-4 fractions, administered once daily. CBCT will be acquired.
Study: NCT05775913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tubal Selective Delivery System (TSDS)
Description: A novel tubal selective delivery catheter system for selective delivery of administered agents to the fallopian tubes without entry of any portion of the catheter into the tubes.